

# Resource Summary Report

Generated by [nidm-terms](#) on Aug 15, 2026

## anti-CD8 (SP239) Rabbit Monoclonal Primary Antibody

RRID:AB\_3697948

Type: Antibody

---

### Proper Citation

(Roche Cat# 09780041001, RRID:AB\_3697948)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3697948](http://antibodyregistry.org/AB_3697948)

**Proper Citation:** (Roche Cat# 09780041001, RRID:AB\_3697948)

**Target Antigen:** CD8

**Host Organism:** Rabbit

**Clonality:** monoclonal

**Comments:** Applications: IHC

**Antibody Name:** anti-CD8 (SP239) Rabbit Monoclonal Primary Antibody

**Description:** This monoclonal targets CD8

**Target Organism:** human

**Clone ID:** SP239

**Antibody ID:** AB\_3697948

**Vendor:** Roche

**Catalog Number:** 09780041001

**Alternative Catalog Numbers:** 790-7176

**Record Creation Time:** 20250702T175020+0000

**Record Last Update:** 20260225T224335+0000

---

### Ratings and Alerts

No rating or validation information has been found for anti-CD8 (SP239) Rabbit Monoclonal Primary Antibody.

No alerts have been found for anti-CD8 (SP239) Rabbit Monoclonal Primary Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

An J, et al. (2026) Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer. Med (New York, N.Y.), 101214.

Tran B, et al. (2026) Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 2850.